Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 16/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19307750 | 0.92 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL92984 | 0.92 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL25020556 | 0.92 | SLC22A2 (0.75) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17285475 | 0.87 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL20822030 | 0.87 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL83236 | 0.87 | SLC22A2 (0.73) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19313899 | 0.86 | SLC22A2 (0.72) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18864091 | 0.85 | SLC22A2 (0.59) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL81251 | 0.83 | SLC22A2 (0.57) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL18423631 | 0.82 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273065-B2 | Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | SLC22A2 2899/4885CYP3A4 36/4885TMEM97 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.